phenylalanine has been researched along with carbamates in 127 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 12 (9.45) | 18.7374 |
1990's | 13 (10.24) | 18.2507 |
2000's | 48 (37.80) | 29.6817 |
2010's | 24 (18.90) | 24.3611 |
2020's | 30 (23.62) | 2.80 |
Authors | Studies |
---|---|
Batshaw, M; Brusilow, S; Walser, M | 1 |
Hassan, A; Santolucito, JA | 1 |
Czernilofsky, AP; Kuechler, E | 1 |
Collatz, EE; Czernilofsky, AP; Kuechler, E; Stöffler, G | 1 |
Neurath, H; Robinson, NC; Walsh, KA | 1 |
Kleinkauf, H; Lipmann, F; Roskoski, R | 1 |
Lynn, KR | 1 |
Lindsay, DG; Loge, O; Losert, W; Shall, S | 1 |
Powers, JC; Robillard, GT; Wilcox, PE | 1 |
Coffey, JJ | 1 |
Bloom, BR; Ishizaka, T; Quan, PC | 1 |
Schulten, HR | 1 |
Bakkali-Nadi, A; Malaisse, WJ; Malaisse-Lagae, F | 1 |
Gahm, KH; Stalcup, AM | 1 |
Brasseur, R; Lins, L; Malaisse, WJ | 1 |
Malaisse, WJ | 2 |
Bakkali Nadi, A; Malaisse, WJ; Zhang, TM | 1 |
Kikuchi, M | 2 |
Fuhlendorff, J; Ladrière, L; Leclercq-Meyer, V; Malaisse, WJ | 1 |
Grgas, B; Kovarik, Z; Radić, Z; Reiner, E; Simeon-Rudolf, V; Skrinjarić-Spoljar, M | 1 |
Asao, T; Fukushima, M; Kakegawa, H; Katunuma, N; Matsui, A; Murata, E; Tada, Y; Tsuge, H; Tsuzuki, H; Turk, D; Turk, V | 1 |
Dunning, BE; Hu, S; Wang, S | 3 |
Smits, P; Tack, CJ | 1 |
Bokvist, K; Buschard, K; Gromada, J; Holst, JJ; Hoy, M; Thomsen, MK | 1 |
Bell, PA; Boettcher, BR; Dunning, BE; Fanelli, B; Geisse, S; Hu, S; Schmitz, R; Wang, S | 1 |
Füchtenbusch, M; Schatz, H; Standl, E | 1 |
Landgraf, R | 1 |
Kalbag, JB; McLeod, JF; Nedelman, JR; Walter, YH | 1 |
de Souza, CJ; Dunning, BE; Lozito, R; Russo, P | 1 |
Dunning, BE; Foley, JE; Pratley, RE | 1 |
Abell, AD; Harvey, AJ | 1 |
Hu, S; Wang, S | 1 |
Sternon, J | 1 |
Dornhorst, A | 1 |
Nelson, G | 1 |
Koivisto, V | 1 |
Hu, S | 1 |
Ahmann, AJ; Riddle, MC | 1 |
Bokvist, K; Gotfredsen, CF; Gromada, J; Hansen, BS; Høy, M; Lindström, P; Olsen, HL; Rorsman, P; Thomsen, MK | 1 |
Ashcroft, FM; Carr, RD; Christensen, IT; Hansen, AM; Hansen, JB; Wahl, P | 1 |
Davies, MJ | 1 |
Göke, B; Parhofer, KG | 1 |
Deacon, R; Dunning, BE; Foley, JE; Gutierrez, C; Paladini, S; Valentin, MA | 1 |
Birkeland, KI; Bleskestad, IH | 1 |
Bokvist, K; Buschard, K; Gromada, J; Holst, JJ; Høy, M; Krogsgaard Thomsen, M; Lindström, P | 1 |
Hale, PM; Hollander, P; Khutoryansky, N; Klaff, L; McGill, J; Raskin, P; South, SA | 1 |
Yoshida, T; Yoshikawa, T; Yoshioka, K | 1 |
Baron, MA | 1 |
Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
Brazinsky, SA; Farrell, J; Hale, PM; Hassman, DR; Khutoryansky, N; Madder, RD; Rosenstock, J | 1 |
Gall, MA; Lammert, M; Minshall, ME; Nicklasson, L; Palmer, AJ; Roze, S; Spinas, GA; Valentine, WJ | 1 |
Berney, T; Bosco, D; Carr, RD; Donath, MY; Maedler, K; Zuellig, RA | 1 |
Blackburn, GL | 1 |
Li, JW; Tian, HM; Wang, JN; Yu, HL; Zhang, XX; Zhao, GZ | 1 |
Gao, LM; Song, DQ; Yang, P | 1 |
Erkent, U; Ertunc, M; Guc, MO; Ilhan, M; Iskit, AB; Onur, R | 1 |
Scheen, AJ | 1 |
Black, C; Donnelly, P; McIntyre, L; Royle, PL; Shepherd, JP; Thomas, S | 1 |
Bieger, S; Kühner, P; Quast, U; Stephan, D; Winkler, M; Wolff, F | 1 |
Huang, L; Li, J; Li, Q; Li, Y; Liang, J; Liu, Y; Luo, R; Ni, Z; Tian, H; Wang, N; Wu, T; Yu, H | 1 |
Kalliokoski, A; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
Kapoor, JR | 1 |
Backman, JT; Kalliokoski, A; Neuvonen, PJ; Niemi, M | 1 |
Li, C; Wang, L; Wang, S; Xia, J; Zhang, G | 1 |
Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L | 1 |
Davis, SN | 1 |
Aoyagi, K; Nagamatsu, S; Nakamichi, Y; Nishiwaki, C; Ohara-Imaizumi, M | 1 |
Longo, R | 1 |
Kalliokoski, A; Neuvonen, PJ; Niemi, M | 1 |
Blanco, H; Góõmez, MP; Laguna, JJ; Rojas, P; Sánchez, L; Santos, A | 1 |
Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
Busse, R; Kreis, J | 1 |
Jung, JS; Kim, CH; Kim, SJ; Kim, SS; Lim, SM; Park, SH; Sim, YB; Suh, HW | 1 |
Chen, M; Hu, C; Jia, W | 1 |
DeFronzo, RA; Ferrannini, E | 1 |
Black, J; Bream, G; Doekel, R; Emsellem, HA; Feldman, NT; Khayrallah, MA; Lu, Y; Rosenberg, R; Ruoff, C; Swick, TJ | 1 |
Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L | 1 |
Hussar, DA | 2 |
Black, J; Bogan, RK; Bream, G; Carter, LP; Emsellem, H; Feldman, N; Khayrallah, M; Lankford, A; Lu, Y; Ruoff, C | 1 |
Amendola, G; Chouchene, K; Cosconati, S; Ettari, R; Grasso, S; Gut, J; Hellmich, UA; Krauth-Siegel, RL; Previti, S; Rosenthal, PJ; Schirmeister, T; Schmid, I; Ulrich, K; Wagner, A; Wich, PR; Zappalà, M | 1 |
Becker, PM; Black, J; Bream, G; Emsellem, HA; Khayrallah, M; Lankford, A; Lu, Y; Ruoff, C; Scrima, L | 1 |
Baladi, MG; Carter, LP; Forster, MJ; Gatch, MB; Hyman, DL; Janowsky, A; Mailman, RB | 1 |
Carter, LP; Henningfield, JE; Kelsh, D; Lu, Y; Sellers, E; Vince, B; Wang, YG | 1 |
Black, J; Carter, LP; Chen, D; Collop, N; Hedner, J; Lee, L; Lorch, DG; Lu, Y; Pépin, JL; Redline, S; Strollo, PJ | 1 |
Black, J; Carter, LP; Chen, D; Gotfried, M; Lu, Y; Malhotra, A; Rosenberg, R; Schweitzer, PK; Strohl, KP; Wang, H; Zammit, GK | 1 |
Kankam, M; Lu, Y; Zomorodi, K | 1 |
Black, J; Carter, LP; Chen, D; Corser, BC; Dauvilliers, Y; Emsellem, H; Lu, Y; Mayer, G; Plazzi, G; Shapiro, C; Thorpy, MJ; Wang, H | 1 |
Chen, D; Lasseter, K; Lee, L; Marbury, T; Zomorodi, K | 1 |
Gao, J; Yang, J | 1 |
Arcara, A; Benfield, M; Brown, J; Crump, LH; Mospan, C; Mospan, G; Ramey, C; Yang, S | 1 |
Ahmed, M; Baladi, M; Chandler, P; Foldvary-Schaefer, N; Hedner, J; Lee, L; Malhotra, A; Mayer, G; Pepin, JL; Sarmiento, K; Schwab, R; Shapiro, C; Strollo, PJ | 1 |
Black, J; Carter, LP; Chen, D; Dauvilliers, Y; Emsellem, HA; Lammers, GJ; Lee, L; Mayer, G; Menno, D; Plazzi, G; Shapiro, CM; Thorpy, MJ; Villa, KF | 1 |
Javaheri, S | 1 |
Garland, S; Piszczatoski, C; Powell, J | 1 |
Black, J; Carter, LP; Chen, D; Dauvilliers, Y; Emsellem, H; Lammers, GJ; Lee, L; Mayer, G; Plazzi, G; Shapiro, C; Thorpy, MJ | 1 |
Earl, DC; Van Tyle, KM | 1 |
Carter, LP; Chen, D; Lee, L; Swearingen, D; Zomorodi, K | 1 |
Lou, G; Wang, T; Xu, Q; Zhang, L | 1 |
Jha, D; K C, B; Ray, BK; Singh, R; Subedi, R; Thakur, RK | 1 |
Baladi, M; Chandler, P; Lee, L; Malhotra, A; Mayer, G; Rosenberg, R; Schweitzer, PK; Strohl, KP | 1 |
Baladi, M; Bron, M; Rosenberg, R | 1 |
Bron, M; Crosby, RD; Mathias, SD; Menno, DM; Morris, S; Weaver, TE | 1 |
Chen, G; Gao, H; Li, X; Wang, J; Wang, T; Xu, X; Xu, Z; Yang, S | 1 |
Baladi, M; Chandler, P; Gotfried, M; Malhotra, A; Mayer, G; Rosenberg, R; Schweitzer, PK; Strohl, KP; Zammit, GK | 1 |
Alamiri, B; El-Sheshaie, A; Elsori, DH; Naguy, A | 1 |
Cavalli, F; Franceschini, C; Pizza, F; Plazzi, G | 1 |
Béni, S; Fejős, I; Köteles, I; Malanga, M; Szabó, ZI; Tóth, G; Várnai, B | 1 |
Amara, AW; Comella, C; Emsellem, H; Gottwald, MD; Hauser, RA; Jochelson, P; Liu, K; Schweitzer, PK; Steinerman, JR; Sterkel, AL; Videnovic, A; Zomorodi, K | 1 |
Bujanover, S; Dauvilliers, Y; Gotfried, M; Malhotra, A; Rosenberg, R; Scheckner, B; Schweitzer, PK; Thorpy, MJ; Zammit, G | 1 |
Bron, M; Bujanover, S; Kratochvil, D; Lucas, E; Menno, D; Patel, D; Ronnebaum, S; Stepnowsky, C | 1 |
Belliard, S; Berrebi-Bertrand, I; Finance, O; Giret, M; Krief, S; Lecomte, JM; Ligneau, X; Nagmar, I; Perrin, D; Robert, P; Schwartz, JC; Uguen, M | 1 |
Ahmed, M; Baladi, M; Bron, M; Chandler, P; Foldvary-Schaefer, N; Hedner, J; Lee, L; Malhotra, A; Mayer, G; Pepin, JL; Sarmiento, K; Schwab, R; Shapiro, C; Strollo, PJ; Weaver, TE | 1 |
Blom, TJ; Guerdjikova, AI; McElroy, SL; Mori, N; Romo-Nava, F | 1 |
Asin, J; Carter, LP; Chen, D; de Vries, N; Donjacour, CEHM; Janssen, H; Lammers, GJ; Overeem, S; Ramaekers, JG; Vermeeren, A; Vinckenbosch, F; Vonk, PE; Wang, G; Zhou, K | 1 |
Armstrong, DW; Berkecz, R; Forró, E; Ilisz, I; Péter, A; Shahmohammadi, S; Tanács, D | 1 |
Baldys, B; Chen, A; Foley, C; Hyman, D; Ito, D; Parks, GS; Singh, H; Thorpy, MJ | 1 |
Bahrami, K; Järvinen, J; Rautio, J; Srisongkram, T; Timonen, J; Weerapreeyakul, N | 1 |
Babson, K; Benca, RM; Bujanover, S; Krystal, AD; Lee, L; Malhotra, A; Rosenberg, R; Schweitzer, PK; Strohl, KP | 1 |
Carter, LP; Chen, D; Lammers, GJ; Overeem, S; Ramaekers, JG; Vermeeren, A; Vinckenbosch, F; Wang, G; Zhou, K | 1 |
34 review(s) available for phenylalanine and carbamates
Article | Year |
---|---|
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestinal Absorption; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Reference Values; Stereoisomerism | 1996 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Nateglinide; Phenylalanine; Piperidines | 2000 |
Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Topics: Animals; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Piperidines | 2001 |
[New drugs].
Topics: Amdinocillin; Carbamates; Clopidogrel; Cyclohexanes; Drug Interactions; Humans; Hypoglycemic Agents; Nateglinide; Patient Selection; Penicillins; Phenylalanine; Piperidines; Platelet Aggregation Inhibitors; Pneumococcal Vaccines; Raloxifene Hydrochloride; Safety; Selective Estrogen Receptor Modulators; Ticlopidine | 2001 |
Insulinotropic meglitinide analogues.
Topics: Adult; Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Piperidines; Rats | 2001 |
[Insulin analogs and new oral antidiabetic drugs].
Topics: Administration, Oral; Carbamates; Cyclohexanes; Diabetes Mellitus; Dose-Response Relationship, Drug; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Piperidines; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Current oral agents for type 2 diabetes. Many options, but which to choose when?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Glycoside Hydrolases; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Receptors, Cytoplasmic and Nuclear; Sulfonylurea Compounds; Transcription Factors | 2002 |
Insulin secretagogues.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Sulfonylurea Compounds; United Kingdom | 2002 |
[Structures and mechanisms for non SU insulin secretagogues].
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Calcium Channels; Carbamates; Cyclohexanes; Exocytosis; Humans; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Isoindoles; Nateglinide; Organ Specificity; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors | 2002 |
[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines | 2003 |
Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Topics: Anti-Bacterial Agents; Area Under Curve; Biological Availability; Biotransformation; Carbamates; Cyclohexanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Fasting; Food-Drug Interactions; Humans; Hypoglycemic Agents; Intestinal Absorption; Nateglinide; Phenylalanine; Piperidines; Postprandial Period | 2007 |
Meglitinide analogues for type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic | 2007 |
Drugs for type 2 diabetes.
Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Piperidines; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2009 |
Advances in oral therapy for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Thiazolidinediones; United States; Weight Gain | 2000 |
SLCO1B1 polymorphism and oral antidiabetic drugs.
Topics: Administration, Oral; Alleles; Carbamates; Cyclohexanes; Genotype; Haplotypes; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Nateglinide; Organic Anion Transporters; Phenylalanine; Pioglitazone; Piperidines; Polymorphism, Genetic; Rosiglitazone; Thiazolidinediones | 2010 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
Pharmacogenomics of glinides.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inactivation, Metabolic; Insulin; Insulin Secretion; Insulin-Secreting Cells; Isoindoles; KATP Channels; Nateglinide; Pharmacogenetics; Phenylalanine; Piperidines | 2015 |
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Piperidines; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
NewDrugs 2017, part 2.
Topics: Amides; Antibodies, Monoclonal, Humanized; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Therapy; gamma-Cyclodextrins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Peptides; Phenylalanine; Quinoxalines; Sofosbuvir; Sugammadex; Sulfonamides; Sulfones; Thioglycolates; Triazoles; United States; United States Food and Drug Administration | 2017 |
Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Carbamates; Disorders of Excessive Somnolence; Dopamine Uptake Inhibitors; Humans; Narcolepsy; Phenylalanine; Treatment Outcome | 2019 |
Solriamfetol (Sunosi) for excessive daytime sleepiness.
Topics: Adrenergic Uptake Inhibitors; Carbamates; Dopamine Uptake Inhibitors; Humans; Phenylalanine; Randomized Controlled Trials as Topic; Sleepiness | 2019 |
Update on Persistent Excessive Daytime Sleepiness in OSA.
Topics: Carbamates; Disorders of Excessive Somnolence; Humans; Modafinil; Phenylalanine; Piperidines; Sleep Apnea, Obstructive; Wakefulness-Promoting Agents | 2020 |
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.
Topics: Carbamates; Clinical Trials as Topic; Disorders of Excessive Somnolence; Humans; Narcolepsy; Phenylalanine; Sleep Apnea, Obstructive; Sleepiness; Treatment Outcome; United States; United States Food and Drug Administration; Wakefulness-Promoting Agents | 2020 |
New pharmacologic agents for insomnia and hypersomnia.
Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans; Orexin Receptor Antagonists; Phenylalanine; Piperidines; Pyridines; Pyrimidines; Sleep Aids, Pharmaceutical; Sleep Apnea, Obstructive; Sleep Initiation and Maintenance Disorders; Trazodone; Triazoles; Zolpidem | 2020 |
[Advances in treatment of narcolepsy].
Topics: Carbamates; Cataplexy; Drug Development; Humans; Narcolepsy; Phenylalanine; Piperidines | 2020 |
Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
Topics: Carbamates; Disorders of Excessive Somnolence; Humans; Narcolepsy; Phenylalanine; Sleep Apnea, Obstructive | 2020 |
Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials.
Topics: Adult; Carbamates; Disorders of Excessive Somnolence; Humans; Narcolepsy; Phenylalanine; Randomized Controlled Trials as Topic; Sleep Apnea, Obstructive; Sleepiness | 2021 |
A practical guide to the pharmacological and behavioral therapy of Narcolepsy.
Topics: Behavior Therapy; Carbamates; Counseling; Humans; Modafinil; Narcolepsy; Phenylalanine; Piperidines; Wakefulness-Promoting Agents | 2021 |
Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
Topics: Benzhydryl Compounds; Carbamates; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Modafinil; Phenylalanine; Sleep Apnea, Obstructive; Treatment Outcome | 2021 |
31 trial(s) available for phenylalanine and carbamates
Article | Year |
---|---|
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestinal Absorption; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Reference Values; Stereoisomerism | 1996 |
Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Body Weight; Carbamates; Cross-Over Studies; Cyclohexanes; Female; Food; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Kinetics; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Placebos; Time Factors | 2001 |
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Topics: Area Under Curve; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Safety | 2003 |
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Topics: Biomarkers; Body Mass Index; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Time Factors | 2004 |
[Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Topics: Adult; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2005 |
Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
Topics: Adult; Age of Onset; Aged; Area Under Curve; Asian People; Blood Glucose; Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2007 |
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Topics: Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Carbamates; Chromatography, Liquid; Cyclohexanes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Genotype; Half-Life; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Metabolic Clearance Rate; Molecular Structure; Nateglinide; Organic Anion Transporters; Pharmacogenetics; Phenylalanine; Piperidines; Polymorphism, Single Nucleotide; Tablets; Tandem Mass Spectrometry | 2008 |
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Carbamates; Cyclohexanes; Female; Haplotypes; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Nateglinide; Organic Anion Transporters; Phenylalanine; Piperidines; Time Factors | 2008 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2009 |
Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
Topics: Adult; Aged; Carbamates; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Narcolepsy; Phenylalanine; Sleep Stages; Treatment Outcome; Wakefulness; Wakefulness-Promoting Agents | 2016 |
Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes.
Topics: Adult; Carbamates; Cross-Over Studies; Female; Humans; Male; Narcolepsy; Phenylalanine; Sleep; Time Factors; Treatment Outcome; Wakefulness; Wakefulness-Promoting Agents | 2017 |
Identifying clinically important difference on the Epworth Sleepiness Scale: results from a narcolepsy clinical trial of JZP-110.
Topics: Adult; Area Under Curve; Carbamates; Double-Blind Method; Female; Humans; Male; Narcolepsy; Phenylalanine; ROC Curve; Severity of Illness Index; Treatment Outcome; Wakefulness-Promoting Agents | 2017 |
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.
Topics: Adrenergic Uptake Inhibitors; Adult; Carbamates; Cross-Over Studies; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Phentermine; Phenylalanine; Substance-Related Disorders; Young Adult | 2018 |
Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
Topics: Adult; Aged; Carbamates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Phenylalanine; Sleep Apnea, Obstructive; Sleepiness; Treatment Outcome; Wakefulness | 2019 |
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
Topics: Adult; Aged; Carbamates; Disorders of Excessive Somnolence; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Phenylalanine; Sleep Apnea, Obstructive | 2019 |
A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food.
Topics: Adult; Area Under Curve; Biological Availability; Carbamates; Cross-Over Studies; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Phenylalanine; Therapeutic Equivalency | 2019 |
A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
Topics: Adult; Carbamates; Double-Blind Method; Female; Humans; Male; Middle Aged; Narcolepsy; Phenylalanine; Sleep Latency; Sleepiness; Treatment Outcome; Wakefulness-Promoting Agents; Young Adult | 2019 |
Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
Topics: Adult; Aged; Carbamates; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Models, Biological; Neurotransmitter Uptake Inhibitors; Phenylalanine; Renal Dialysis; Renal Insufficiency | 2019 |
Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
Topics: Carbamates; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Narcolepsy; Phenylalanine; Sleep Apnea, Obstructive; Sleepiness; Treatment Outcome | 2020 |
Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
Topics: Adult; Carbamates; Disorders of Excessive Somnolence; Double-Blind Method; Efficiency; Female; Humans; Male; Narcolepsy; Phenylalanine; Physical Functional Performance; Quality of Life; Surveys and Questionnaires; Wakefulness | 2020 |
Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
Topics: Adult; Carbamates; Cataplexy; Disorders of Excessive Somnolence; Double-Blind Method; Female; Humans; Male; Narcolepsy; Phenylalanine; Treatment Outcome; Wakefulness | 2020 |
A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
Topics: Adrenergic Uptake Inhibitors; Adult; Carbamates; Cross-Over Studies; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Phenylalanine; Young Adult | 2021 |
Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy.
Topics: Carbamates; Continuous Positive Airway Pressure; Disorders of Excessive Somnolence; Humans; Phenylalanine; Sleep Apnea, Obstructive; Treatment Outcome | 2021 |
Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea.
Topics: Adolescent; Adult; Aged; Carbamates; Female; Humans; Male; Middle Aged; Narcolepsy; Phenylalanine; Sleep Apnea, Obstructive; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2021 |
Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
Topics: Adolescent; Adult; Aged; Carbamates; Disorders of Excessive Somnolence; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Patient Compliance; Phenylalanine; Sleep; Sleep Apnea, Obstructive; Wakefulness; Young Adult | 2021 |
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
Topics: Adult; Carbamates; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Parkinson Disease; Phenylalanine | 2021 |
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
Topics: Carbamates; Disorders of Excessive Somnolence; Humans; Incidence; Narcolepsy; Phenylalanine; Randomized Controlled Trials as Topic; Sleep Apnea, Obstructive; Treatment Outcome | 2022 |
Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder.
Topics: Binge-Eating Disorder; Carbamates; Double-Blind Method; Humans; Phenylalanine; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea.
Topics: Carbamates; Disorders of Excessive Somnolence; Humans; Phenylalanine; Sleep Apnea, Obstructive | 2022 |
Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.
Topics: Carbamates; Depression; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Narcolepsy; Phenylalanine; Sleep Apnea, Obstructive; Treatment Outcome | 2022 |
Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial.
Topics: Adult; Automobile Driving; Carbamates; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Narcolepsy; Phenylalanine | 2023 |
64 other study(ies) available for phenylalanine and carbamates
Article | Year |
---|---|
Treatment of carbamyl phosphate synthetase deficiency with keto analogues of essential amino acids.
Topics: Adolescent; Amino Acids; Amino Acids, Essential; Ammonia; Carbamates; Child; Child, Preschool; Circadian Rhythm; Female; Humans; Infant; Infant, Newborn; Injections, Intravenous; Isoleucine; Keto Acids; Leucine; Liver; Methionine; Nitrogen; Phenylalanine; Phosphotransferases; Urea; Valine | 1975 |
Pharmacological effects of carbaryl. II. Modification of serotonin metabolism in the rat brain.
Topics: Adrenocorticotropic Hormone; Animals; Brain; Brain Chemistry; Carbamates; Corticosterone; Hydroxyindoleacetic Acid; Male; Mixed Function Oxygenases; Naphthalenes; Phenylalanine; Rats; Reserpine; Serotonin; Stimulation, Chemical; Tryptophan | 1971 |
Affinity label for the tRNA binding site on the Escherichia coli ribosome.
Topics: Bacterial Proteins; Binding Sites; Carbamates; Centrifugation, Density Gradient; Chemical Phenomena; Chemistry; Electrophoresis, Disc; Escherichia coli; Molecular Weight; Nitrobenzenes; Nitrophenols; Phenylalanine; Polynucleotides; Ribosomes; RNA, Transfer; Sodium Dodecyl Sulfate; Tritium; Uracil Nucleotides | 1972 |
Proteins at the tRNA binding sites of Escherichia coli ribosomes.
Topics: Animals; Antigen-Antibody Complex; Autoradiography; Bacterial Proteins; Binding Sites; Carbamates; Centrifugation, Density Gradient; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Immunoassay; Molecular Weight; Nitrophenols; Phenylalanine; Protein Binding; Puromycin; Rabbits; Ribosomes; RNA, Transfer; Tritium | 1974 |
The relation of the -amino group of trypsin to enzyme function and zymogen activation.
Topics: Benzoates; Carbamates; Carbon Isotopes; Catalysis; Chemical Phenomena; Chemistry; Cyanates; Enzyme Activation; Guanidines; Isoflurophate; Isoleucine; Kinetics; Nitrobenzenes; Phenylalanine; Potassium; Protein Denaturation; Structure-Activity Relationship; Succinimides; Thiocarbamates; Thiocyanates; Trypsin; Trypsin Inhibitors; Trypsinogen | 1973 |
Pantetheine-linked peptide intermediates in gramicidin S and tyrocidine biosynthesis.
Topics: Asparagine; Carbamates; Carbon Isotopes; Chromatography, Gel; Chromatography, Thin Layer; Enzymes; Hydroxybutyrates; Pepsin A; Peptide Biosynthesis; Peptide Chain Initiation, Translational; Peptides; Phenylalanine; Proline; Sulfhydryl Compounds; Tyrothricin | 1971 |
Effects of -radiation on concentrated solutions of -chymotrypsin.
Topics: Air; Albumins; Anilides; Carbamates; Caseins; Chymotrypsin; Cobalt Isotopes; Electrophoresis; Esters; Hemoglobins; Hydrochloric Acid; Imidazoles; Leucine; Nitro Compounds; Nitrogen; Nitrophenols; Peptides; Phenylalanine; Radiation Effects; Radiochemistry; Riboflavin; Solutions; Structure-Activity Relationship; Tryptophan; Tyrosine | 1972 |
Carbamyl- and methylthiocarbamylinsulins.
Topics: Animals; Binding Sites; Biological Assay; Blood Glucose; Carbamates; Cattle; Chemical Phenomena; Chemistry; Chromatography, Ion Exchange; Chromatography, Thin Layer; Cyanates; Guinea Pigs; Insulin; Insulin Antibodies; Isoelectric Focusing; Male; Oxidation-Reduction; Phenylalanine; Rabbits; Radioimmunoassay; Sulfites; Thiocarbamates; Thiocyanates | 1972 |
A chemical and crystallographic study of carbamyl-chymotrypsin A.
Topics: Acetates; Amino Acids; Animals; Binding Sites; Carbamates; Carbon Isotopes; Cattle; Chemical Phenomena; Chemistry; Chromatography, Gel; Chromatography, Ion Exchange; Chymotrypsin; Cyanates; Cyanides; Cyanogen Bromide; Cysteine; Glycine; Models, Structural; Nitrophenols; Pancreas; Phenylalanine; Protein Conformation; Serine; Succinates; Water; X-Ray Diffraction | 1972 |
Inducible synthesis of bacterial luciferase: specificity and kinetics of induction.
Topics: Amines; Amino Acids; Ammonium Chloride; Arginine; Azo Compounds; Bacteria; Bacterial Proteins; Carbamates; Carbon Isotopes; Chloramphenicol; Enzyme Induction; Fluorine; Fluorouracil; Guanidines; Kinetics; Light; Luciferases; Marine Biology; Nitrates; Phenylalanine; Propylamines; Puromycin; RNA, Messenger; Urea | 1967 |
Studies on the mechanism of NK cell lysis.
Topics: Animals; Arginine; Calcium; Carbamates; Cytotoxicity, Immunologic; Dose-Response Relationship, Immunologic; Female; Immunity, Cellular; Indoles; Male; Mice; Mice, Inbred CBA; Nitrobenzoates; Phenylalanine; Phenylcarbamates; Protease Inhibitors; Tosyllysine Chloromethyl Ketone; Tosylphenylalanyl Chloromethyl Ketone; Tubercidin; Tyrosine | 1982 |
Off-line combination of liquid chromatography and field desorption mass spectrometry: principles and environmental, medical and pharmaceutical applications.
Topics: Barbiturates; Carbamates; Chromatography, High Pressure Liquid; Cyclophosphamide; Humans; Mass Spectrometry; Phenylalanine; Phenylurea Compounds; Reference Values; Thiocarbamates; Tyrosine | 1982 |
Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Female; Glucose; Hypoglycemic Agents; In Vitro Techniques; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Isoindoles; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Rats; Structure-Activity Relationship; Succinates | 1994 |
Capillary zone electrophoresis study of naphthylethylcarbamoylated beta-cyclodextrins.
Topics: Aminobutyrates; beta-Cyclodextrins; Carbamates; Carbohydrate Sequence; Chromatography, High Pressure Liquid; Cyclodextrins; Electrophoresis; Glycine; Molecular Sequence Data; Nitrobenzoates; Phenylalanine; Stereoisomerism | 1995 |
Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family.
Topics: Benzamides; Carbamates; Cyclohexanes; Drug Design; Glyburide; Hypoglycemic Agents; Indoles; Isoindoles; Molecular Conformation; Nateglinide; Phenylalanine; Piperidines; Stereoisomerism; Structure-Activity Relationship; Sulfonylurea Compounds | 1995 |
Insulinotropic action of meglitinide analogues: modulation by an activator of ATP-sensitive K+ channels and high extracellular K+ concentrations.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Female; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Isoindoles; Nateglinide; Phenylalanine; Piperidines; Potassium; Rats | 1995 |
Effects of the methyl esters of pyruvate, succinate and glutamate on the secretory response to meglitinide analogues in rat pancreatic islets.
Topics: Animals; Carbamates; Cells, Cultured; Cyclohexanes; Glucose; Glutamates; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Isoindoles; Nateglinide; Phenylalanine; Piperidines; Pyruvates; Rats; Succinates | 1996 |
Stimulation of insulin and somatostatin release by two meglitinide analogs.
Topics: Animals; Benzamides; Blood Glucose; Carbamates; Cyclohexanes; Female; Glucagon; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nateglinide; Perfusion; Phenylalanine; Piperidines; Rats; Rats, Wistar; Somatostatin | 1997 |
Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline.
Topics: Acetylcholinesterase; Amino Acids; Animals; Binding Sites; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Humans; Isoleucine; Kinetics; Mice; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Phenylalanine; Protein Conformation; Quaternary Ammonium Compounds; Terbutaline | 1999 |
Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo.
Topics: Animals; Carbamates; Cathepsin L; Cathepsins; Cells, Cultured; Chromatography, High Pressure Liquid; Computer Graphics; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Drug Design; Endopeptidases; Humans; Intestine, Small; Kinetics; Leucine; Liver; Lysosomes; Mice; Phenylalanine; Rats; Recombinant Proteins; Spleen; Structure-Activity Relationship; Substrate Specificity; Time Factors | 1999 |
Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channels.
Topics: Animals; Aorta, Thoracic; Carbamates; Cardiovascular System; Coronary Vessels; Cyclohexanes; Glyburide; Heart; Hypoglycemic Agents; Islets of Langerhans; Male; Muscle, Smooth, Vascular; Nateglinide; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Rats; Rats, Sprague-Dawley; Swine | 1999 |
Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells.
Topics: Animals; ATP-Binding Cassette Transporters; Calcium; Carbamates; Cyclohexanes; Eating; Electrophysiology; Exocytosis; Glucagon; Glucose; Hypoglycemic Agents; In Vitro Techniques; Islets of Langerhans; KATP Channels; Kinetics; Male; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Inwardly Rectifying; Rats; Rats, Inbred Lew; Stimulation, Chemical | 1999 |
Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Topics: Animals; ATP-Binding Cassette Transporters; Binding, Competitive; Carbamates; Cell Membrane; Cell Separation; Cells, Cultured; Cyclohexanes; Glucose; Glyburide; Glycosyltransferases; Humans; Hypoglycemia; Hypoglycemic Agents; In Vitro Techniques; Insulin; Islets of Langerhans; KATP Channels; Kinetics; Male; Membrane Proteins; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Inwardly Rectifying; Rats; Rats, Sprague-Dawley; Repressor Proteins; Saccharomyces cerevisiae Proteins; Sulfonylurea Compounds | 2000 |
Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions.
Topics: Animals; Blood Glucose; Carbamates; Cyclohexanes; Food; Glipizide; Glucagon; Insulin; Insulin Secretion; Male; Nateglinide; Phenylalanine; Piperidines; Rats; Rats, Sprague-Dawley | 2001 |
Alpha-ketoester-based photobiological switches: synthesis, peptide chain extension and assay against alpha-chymotrypsin.
Topics: Binding Sites; Biochemistry; Carbamates; Chymotrypsin; Drug Evaluation, Preclinical; Peptides; Phenylalanine; Photochemistry; Serine Proteinase Inhibitors; Structure-Activity Relationship; Ultraviolet Rays | 2001 |
Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cell.
Topics: Animals; Calcium Channels; Carbamates; Cyclohexanes; Dose-Response Relationship, Drug; Electric Stimulation; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Membrane Potentials; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Piperidines; Potassium Channels; Rats; Rats, Sprague-Dawley | 2001 |
Type 2 diabetes management.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2002 |
Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
Topics: Adenosine Triphosphate; Animals; Carbamates; Cyclohexanes; Dose-Response Relationship, Drug; Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Membrane Potentials; Nateglinide; Phenylalanine; Piperidines; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds; Time Factors | 2002 |
Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis.
Topics: Animals; Calcium; Carbamates; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclohexanes; Delayed Rectifier Potassium Channels; Exocytosis; Growth Hormone; Growth Hormone-Releasing Hormone; Hypoglycemic Agents; Male; Membrane Potentials; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Piperidines; Pituitary Gland; Potassium; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Rats; Rats, Sprague-Dawley | 2002 |
Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
Topics: ATP-Binding Cassette Transporters; Binding, Competitive; Carbamates; Cell Line; Cyclohexanes; Drug Interactions; Electrophysiology; Humans; Islets of Langerhans; Nateglinide; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors; Tolbutamide | 2002 |
Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
Topics: Animals; Carbamates; Cyclohexanes; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Nateglinide; Phenylalanine; Piperidines; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds | 2001 |
Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas.
Topics: Animals; Carbamates; Cyclohexanes; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Phenylalanine; Piperidines; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds | 2001 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Topics: Animals; Blood Glucose; Carbamates; Cyclohexanes; Fatty Acids, Nonesterified; Food; Glucagon; Hypoglycemic Agents; Insulin; Insulin Secretion; Kinetics; Macaca fascicularis; Male; Nateglinide; Phenylalanine; Piperidines | 2003 |
[Differences between oral antidiabetics].
Topics: Administration, Oral; Carbamates; Cyclohexanes; Diabetes Mellitus; Glipizide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2003 |
Repaglinide at a cellular level.
Topics: Animals; Carbamates; Cyclohexanes; Electrophysiology; Exocytosis; Hypoglycemic Agents; Islets of Langerhans; Membrane Potentials; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Potassium Channels; Rats | 2002 |
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
Topics: Adiponectin; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Nateglinide; Phenylalanine; Piperidines; Proteins; Sulfonylurea Compounds | 2003 |
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2003 |
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Topics: Carbamates; Cohort Studies; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cyclohexanes; Decision Support Systems, Clinical; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Male; Metformin; Middle Aged; Models, Econometric; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Piperidines; Quality-Adjusted Life Years | 2004 |
Sulfonylurea induced beta-cell apoptosis in cultured human islets.
Topics: Adult; Aged; Apoptosis; Calcium; Carbamates; Cells, Cultured; Cyclohexanes; Dose-Response Relationship, Drug; Glyburide; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2005 |
Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Eating; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines | 2004 |
[Synthesis and insulinotropic activity of 2-benzylidenesuccinic acid derivatives].
Topics: Animals; Benzylidene Compounds; Blood Glucose; Carbamates; Cyclohexanes; Hypoglycemic Agents; Indoles; Isoindoles; Mice; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Structure-Activity Relationship; Succinates | 2005 |
Glibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Blood Pressure; Carbamates; Cyclohexanes; Disease Models, Animal; Drug Interactions; Endotoxemia; Glyburide; Heart Atria; Heart Conduction System; Lipopolysaccharides; Male; Myocardial Ischemia; Nateglinide; Phenylalanine; Piperidines; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Tetraethylammonium; Time Factors; Ventricular Fibrillation; Ventricular Premature Complexes | 2007 |
Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
Topics: Amino Acid Substitution; Animals; ATP-Binding Cassette Transporters; Binding Sites; Binding, Competitive; Carbamates; Cell Line; Cyclohexanes; Dose-Response Relationship, Drug; Glyburide; Hypoglycemic Agents; KATP Channels; Ligands; Mice; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Protein Binding; Radioligand Assay; Rats; Receptors, Drug; Sulfonylurea Compounds; Sulfonylurea Receptors; Transfection | 2007 |
Postprandial hyperglycemia: are all sulfonylureas created equal?
Topics: Carbamates; Cyclohexanes; Glipizide; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Sulfonylurea Compounds | 2008 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones | 2009 |
Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations.
Topics: Animals; Calcium; Carbamates; Cell Fusion; Cells, Cultured; Cyclohexanes; Exocytosis; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Nateglinide; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2009 |
Diabetes under control: Understanding oral antidiabetic agents.
Topics: Administration, Oral; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2010 |
Hypersensitivity to repaglinide.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Erythema; Exanthema; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patch Tests; Phenylalanine; Piperidines | 2011 |
From evidence assessments to coverage decisions?: the case example of glinides in Germany.
Topics: Carbamates; Cost Control; Cost-Benefit Analysis; Costs and Cost Analysis; Cyclohexanes; Diabetes Mellitus; Eligibility Determination; Evidence-Based Medicine; Germany; Health Care Reform; Health Policy; Humans; Hypoglycemic Agents; Insurance Coverage; Nateglinide; National Health Programs; Phenylalanine; Piperidines; Prescription Drugs; Reimbursement Mechanisms; Technology Assessment, Biomedical | 2012 |
Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.
Topics: Animals; Blood Glucose; CA3 Region, Hippocampal; Carbamates; Cell Death; Corticosterone; Cyclohexanes; Excitatory Amino Acid Agonists; Hypoglycemic Agents; Infusions, Intraventricular; Insulin; Kainic Acid; Male; Mice; Mice, Inbred ICR; Nateglinide; Neurons; Phenylalanine; Piperidines | 2014 |
Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Topics: Area Under Curve; Carbamates; Cyclohexanes; Databases, Factual; Diabetes Mellitus, Type 2; Drug Interactions; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Medical Informatics; Nateglinide; Pharmacoepidemiology; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2017 |
Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).
Topics: Antimalarials; Carbamates; Cathepsin L; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dipeptides; HeLa Cells; Humans; Hydrogen Bonding; Malaria; Molecular Docking Simulation; Molecular Dynamics Simulation; Neglected Diseases; Phenylalanine; Plasmodium falciparum; Stereoisomerism; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2017 |
Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor.
Topics: Animals; Behavior, Animal; Biological Transport; Carbamates; Cell Line; Dopamine; Locomotion; Male; Neurochemistry; Norepinephrine; Phenylalanine; Rats; Rats, Sprague-Dawley | 2018 |
Drug updates and approvals: 2019 in review.
Topics: Antibodies, Monoclonal; Azetidines; Benzyl Compounds; beta-Cyclodextrins; Carbamates; Clobetasol; Drug Approval; Drug Combinations; Formoterol Fumarate; Heterocyclic Compounds, 3-Ring; Humans; Lamivudine; Nicotinic Acids; Oxazines; Phenylalanine; Piperazines; Pregnanolone; Pyridones; Tropanes; United States; United States Food and Drug Administration | 2019 |
New Drugs 2020, part 1.
Topics: Antibodies, Monoclonal; Benzofurans; Carbamates; Drug Approval; Humans; Phenylalanine; Piperidines; Purines; Tetracyclines; United States; United States Food and Drug Administration | 2020 |
Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.
Topics: Adult; Carbamates; Disorders of Excessive Somnolence; Humans; Narcolepsy; Phenylalanine; Sleep Apnea, Obstructive | 2021 |
Solriamfetol for attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Carbamates; Humans; Phenylalanine | 2022 |
Enantioseparation of solriamfetol and its major impurity phenylalaninol by capillary electrophoresis using sulfated gamma cyclodextrin.
Topics: Carbamates; Electrophoresis, Capillary; gamma-Cyclodextrins; Phenylalanine; Stereoisomerism; Sulfates | 2021 |
Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Carbamates; Corpus Striatum; Disorders of Excessive Somnolence; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Drug Evaluation, Preclinical; Drug Inverse Agonism; Feeding Behavior; Histamine Antagonists; Locomotion; Mice; Modafinil; Narcolepsy; Neostriatum; Norepinephrine Plasma Membrane Transport Proteins; Nucleus Accumbens; Phenylalanine; Piperidines; Receptors, Histamine H3; Sleep Apnea, Obstructive; Wakefulness-Promoting Agents | 2021 |
Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Topics: Adult; Carbamates; Disorders of Excessive Somnolence; Humans; Narcolepsy; Phenylalanine; Quality of Life; Sleep Apnea, Obstructive | 2021 |
Macrocyclic glycopeptides- and derivatized cyclofructan-based chiral stationary phases for the enantioseparation of fluorinated ß-phenylalanine analogs.
Topics: Carbamates; Chromatography, High Pressure Liquid; Glycopeptides; Phenylalanine; Stereoisomerism; Vancomycin | 2022 |
Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario.
Topics: Adult; Carbamates; Disorders of Excessive Somnolence; Female; Humans; Male; Middle Aged; Phenylalanine; Retrospective Studies; Sleep Apnea, Obstructive | 2022 |
Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma.
Topics: Amino Acids; Benzodioxoles; Biological Transport; Carbamates; HEK293 Cells; Humans; Large Neutral Amino Acid-Transporter 1; Leucine; Melanoma; Phenols; Phenylalanine; Prodrugs; Syndrome | 2022 |